Anika Therapeutics ANIK US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's US — revenue?
- Anika Therapeutics (ANIK) reported US — revenue of $18.53M in Q1 2026.
- How has Anika Therapeutics's US — revenue changed year-over-year?
- Anika Therapeutics's US — revenue increased by 13.0% year-over-year, from $16.4M to $18.53M.
- What is the long-term trend for Anika Therapeutics's US — revenue?
- Over 4 years (2021 to 2025), Anika Therapeutics's US — revenue has grown at a -11.4% compound annual growth rate (CAGR), from $113.83M to $70.14M.
- What does US — revenue mean?
- This metric represents the total revenue generated from contracts with customers within the United States geographic segment, excluding any assessed taxes. It serves as a primary indicator of the company's core commercial performance and market demand for its orthopedic products in the domestic market. Tracking this figure allows investors to assess the underlying growth trajectory of the business independent of tax-related fluctuations.